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a b s t r a c t
The protracted accumulation of amyloid-b (Ab) is a major pathologic hallmark of Alzheimer’s disease and
may trigger secondary pathological processes that include neurovascular damage. This study was aimed
at investigating long-term effects of Ab burden on cerebral blood volume of arterioles and pial arteries
(CBVa), possibly present before manifestation of dementia. Ab burden was assessed by 11C Pittsburgh
compound-B positron emission tomography in 22 controls and 18 persons with mild cognitive impair-
ment (MCI), [ages: 75(6) years]. After 2 years, inﬂow-based vascular space occupancy at ultra-high ﬁeld
strength of 7-Tesla was administered for measuring CBVa, and neuropsychological testing for cognitive
decline. Crushing gradients were incorporated during MR-imaging to suppress signals from fast-ﬂowing
blood in large arteries, and thereby sensitize inﬂow-based vascular space occupancy to CBVa in pial
arteries and arterioles. CBVa was signiﬁcantly elevated in MCI compared to cognitively normal controls
and regional CBVa related to local Ab deposition. For both MCI and controls, Ab burden and follow-up
CBVa in several brain regions synergistically predicted cognitive decline over 2 years. Orbitofrontal
CBVa was positively associated with apolipoprotein E e4 carrier status. Increased CBVa may reﬂect long-
term effects of region-speciﬁc pathology associated with Ab deposition. Additional studies are needed to
clarify the role of the arteriolar system and the potential of CBVa as a biomarker for Ab-related vascular
downstream pathology.
 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Late-onset Alzheimer’s disease (AD) is characterized by a
decade-long preclinical phase and eventually leads to mild cogni-
tive impairment (MCI) as its ﬁrst clinical manifestation (Albert et al.,
2011). Although neuropathological changes in AD are complex and
include cerebrovascular disease, neuroinﬂammation, and aggrega-
tion of pathological tau and other proteins (Elahi and Miller, 2017;
Serrano-Pozo et al., 2011), Ab-burden is considered to represent
earliest brain pathology in AD and possibly trigger a multitude of
pathologic downstream processes (Jack et al., 2010; Ossenkoppele
et al., 2015; Rabinovici et al., 2017; Villemagne et al., 2018). The
advent of positron emission tomography (PET) tracers such as 11C-
Pittsburgh Compound B (PiB) has provided the means to non-
invasively assess the extent of regional amyloid-b (Ab) burden in
older populations (Klunk et al., 2004; Seo et al., 2017; van Bergen
et al., 2018b). By now, a concatenation of studies have
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consistently demonstrated that the risk for cognitive decline and
dementia is closely related to the cerebral accumulation of Ab, as
measured by PET, cerebrospinal ﬂuid, or postmortem examination
(Jansen et al., 2015; Mormino et al., 2009; Roberts et al., 2017).
Moreover, progression of pathology in AD is linked to neurovascular
dysfunction (Iadecola, 2004; Iturria-Medina et al., 2016), as re-
ﬂected by reduced cerebral blood ﬂow (CBF) and also altered blood-
brain barrier permeability (Bell and Zlokovic, 2009; Kisler et al.,
2017; Leeuwis et al., 2017; Ostergaard et al., 2013). The co-
occurrence of AD-typical neurometabolic change and vascular pa-
thology may support the idea of synergistic interaction of vascular
change and neurodegeneration as an aggravating factor for pa-
thology in AD (Gelber et al., 2012; Schreiner et al., 2018; Snowdon
and Nun, 2003; Tyas et al., 2007a,b). Interestingly, apolipoprotein
E e4 (APOE4), which is the strongest known genetic risk factor for
AD (Corder et al., 1993; Verghese et al., 2013), is associated with
accelerated accumulation of Ab, reduced CBF, and impaired blood-
brain barrier function (Janelidze et al., 2017; Thambisetty et al.,
2010). Particularly, reduced brain perfusion (CBF) (Michels et al.,
2016; Thambisetty et al., 2010) and impaired cerebrovascular
reactivity (Suri et al., 2015) have been observed in cognitively
normal APOE4 carriers. Therefore, it is important to assess the as-
sociation between APOE4 and cerebrovascular impairments in AD.
Although the accumulation of Ab in sporadic AD ismainly caused by
decreased clearance (Mawuenyega et al., 2010), clearance capacity
of Ab from the brain depends on interstitial spinal ﬂuid ﬂow in the
paravascular space surrounding arterioles, which is primarily
driven by the arterial pulsation wave from the small blood vessels
(Iliff et al., 2012, 2013; Xie et al., 2013). This indicates that abnor-
malities in arterioles may contribute to accumulation and deposi-
tion of Ab and possibly other toxic solutes related to
neurodegenerative brain dysfunction. Cerebral blood volume (CBV)
is a measure of the quantity of blood in a unit of tissue (Hua et al.,
2018). Although CBV generally is linked to regional tissue meta-
bolism, arteriolar CBV (CBVa) particularly reﬂects the autor-
egulatory capacity of arteriolar vessel resistance, and thus may be
used to investigate cerebrovascular functionality within gray mat-
ter regions (Aaslid et al., 1989; Gröhn et al., 1998; Grubb et al., 1974;
Petrella and Provenzale, 2000; Rane et al., 2016). CBVa may be
assessed by inﬂow vascular space occupancy (iVASO) magnetic
resonance imaging (MRI) (Donahue et al., 2010; Hua et al., 2011a),
and application of ultrahigh ﬁeld strength of 7 Tesla (7T) provides
high signal-to-noise ratios (SNRs) (Hua et al., 2017; Wu et al., 2016).
Recently, reductions in total CBV have been demonstrated in pa-
tients with AD dementia (Harris et al., 1996; Lacalle-Aurioles et al.,
2014; Nielsen et al., 2017b; Uh et al., 2010). Based on these earlier
ﬁndings, we hypothesized that CBVa may be a particularly sensitive
indicator of AD-related graymatter (GM) pathology and thus reﬂect
vascular downstream effects of Ab in the predementia stage. To test
this hypothesis, a nondemented study population comprising
cognitive performance levels fromnormal toMCI, received 11C-PiB-
PET for assessment of regional Ab burden, and as a follow-up after 2
years, iVASO MRI at ultrahigh ﬁeld strength of 7T. In addition, ge-
netic risk for AD as indicated by APOE4 carrier status and cognitive
decline within the study period were used as covariates.
2. Methods
2.1. Participant characteristics
We recruited 18 patients with MCI and 22 cognitively unim-
paired older adults as controls. Patients with MCI and healthy
controls were recruited as part of an ongoing study at our hospital,
andmatched by age and sex, as reported in detail earlier (Gietl et al.,
2015; Schreiner et al., 2014, 2016; Steininger et al., 2014). Exclusion
criteria were any present medication that may affect cognition,
general MRI exclusion criteria, contraindications against veni-
puncture, clinically relevant changes in red blood cell count, any
acute severemedical, neurological, or psychiatric condition, present
or past drug abuse, allergy to the PET tracer 11C-PiB, signiﬁcant
earlier exposure to radiation. The study was conducted in accor-
dance with guidelines issued by the local ethics committee (Kant-
onale Ethikkommission Zurich) andwith the declaration of Helsinki
(World_Medical_Association, 1991). All procedures were approved
by the Kantonale Ethikkommission Zurich. All participants gave
written informed consent before scanning. Each participant had 2
visits approximately 2 years apart (730  277 days) and received
neuropsychological testing at both time points (TP1 and TP2). PET
studies were performed at study inclusion; the 7 Tesla MR se-
quences were administered during the follow-up visit, resulting in
an average delay of 803  203 days between PET and 7T MRI
measures. Demographic data and factors associated with vascular
risk are summarized in Table 1. Isoforms of the APOE gene were
assessed for all participants. Twelve of the participants carried 1 e4
allele and 2 participants carried 2 e4 alleles.
2.2. Neuropsychological testing
All participants received detailed clinical and neuropsychological
examination before they were included in the present study. Partici-
pants were categorized either as cognitively normal or MCI according
to established criteria (Albert et al., 2011). All particiapnts were
screened for cognitive impairment using the Mini-Mental State Ex-
amination (Folstein et al., 1975). Cognitive performance of study par-
ticipants was assessed at TP1 and TP2 based on 4 cognitive tests: (1)
The Revised Boston Naming Test (Nicholas et al., 1988); (2) Digit Spans
Backward (Gregoire andVan der Linden,1997); (3) TrailMaking Test B/
A (Tombaugh, 2004); and (4) Verbal Learning And Memory Test:
delayed recall (Lange et al., 2002). These measures were z-score-
etransformed and averaged to generate a single global cognitive score
for each participant. Longitudinal changes in the cognitive scores were
normalized by the time duration (in years) between the 2 visits.
Table 1
Demographics and test performance of the study population
Variable Controlsa Patients with
MCIa
p Valueb
N 22 18 N/A
Sex (female) 8 6 1
Age (y) 72  5 75  7 0.08
Education (y) 13.64  2.56 15.06  3.28 0.13
Number of APOE4 alleles 7 9 N/A
Body mass index (BMI) 25.24  4.13 24.57  3.83 0.60
Arterial hypertension (N: yes; no) 4; 18 8; 10 0.07
Hypercholesterinemia (N: yes;
no)
4; 18 9; 9 0.03
Present smokers (N: yes; no) 1; 21 0; 18 1
History of past smoking (N: yes;
no)
9; 13 10; 8 0.36
Mini-Mental State Examination
(MMSE), % change per year
0.57  3.6 0.63  5.04 0.4
Boston naming test (BNT), %
change
1.46  4.46 0.19  10.63 0.54
Digit span backward, % change 1.35  21.17 4.89  26.83 0.42
Trail making B/A (TMT B/A), %
change
4.11  35.41 9.21  67.44 0.45
Verbal learning and memory
(VLMT), % change
8.43  28.9 31.49  100.72 0.35
Cognitive performance score (Z),
%SD change
0.9  37.45 6.19  71.54 0.77
a Mean  standard deviation (SD).
b p values from 2-sample t-tests between the 2 groups, or from c2-test for cate-
gorical variables. Neuropsychological scores indicate average % changes in test
performance between study inclusion (TP1) and follow-up (TP2).
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2.3. Magnetic resonance imaging
All scans were performed on a 7T Philips MRI scanner (Philips
Healthcare, Best, The Netherlands). A 32-channel phased-array
head coil (Nova Medical, Wilmington, MA) was used for radio-
frequency reception and a head-only quadrature coil for transmit.
High-resolution anatomical images were acquired with a 3D
magnetization prepared 2 rapid acquisition gradient echoes
(MP2RAGE) sequence (Marques et al., 2010; Van de Moortele et al.,
2009) (voxel ¼ 0.75 mm isotropic). Total scan time on the 7T in-
strument was 50:42 minutes, including 10:43 minutes for per-
forming the MP2RAGE sequence and 8:19 minutes for obtaining
iVASO data.
Three-dimensional iVASO MRI was performed to measure
regional GM CBVa. In iVASOMRI, arterial and arteriolar blood signal
is zeroed out (nulled) by applying a spatially selective inversion in
regions containing major feeding arteries. The difference signal
between the arterial blood nulled scan and a control scan without
blood nulling can then be used to calculate CBVa (Donahue et al.,
2010; Hua et al., 2011c, 2014; Wu et al., 2016). To account for the
heterogeneity of vascular transit times, interleaved nulling and
control images are acquired at multiple postinversion delay times
(TI), and a biophysical model for multi-TI iVASO signals is used to
numerically ﬁt absolute CBVa from the dynamic multi-TI time
course on a voxel-by-voxel basis so that the vascular transit time
can be different in each voxel (Hua et al., 2011c). Crushing gradients
can be incorporated to suppress signals from fast-ﬂowing blood in
large arteries and thereby sensitize this method to CBVa predomi-
nantly in the pial arteries and arterioles, which we refer to here as
arteriolar blood. The iVASO approach was originally developed in a
single-slice mode using a gradient echo echo planar imaging
readout and has now been extended to a 3D sequence with whole-
brain coverage (Hua et al., 2013, 2017). The following iVASO pa-
rameters were used: time of repetition/TI ¼ 10000/1383, 5000/
1093, 3800/884, 3100/714, 2500/533, and 2000/356 ms; 3D fast
gradient echo readout (TE ¼ 2.2 ms); voxel ¼ 3.5  3.5  5 mm3, 20
slices; parallel imaging acceleration (SENSE) ¼ 2  2; crusher gra-
dients of b ¼ 0.3 s/mm2. A reference scan (time of repetition ¼ 20
seconds, other parameters identical) was obtained to determine the
scaling factor M0 in iVASO images so that absolute CBVa values can
be calculated.
2.4. MRI data analysis
The statistical parametric mapping (SPM) software package
(version 8, Wellcome Trust Centre for Neuroimaging, London,
United Kingdom; http://www.ﬁl.ion.ucl.ac.uk/spm/) and other in-
house code programmed in MATLAB (MathWorks, Natick, MA,
USA) were used for image analysis. iVASO images were motion-
corrected using the realignment routine in SPM. As the nulling
and control scans in iVASO are acquired in an interleaved order and
the MR signal difference between nulling and control images is
usually less than 1%e3% of the total signal (because it reﬂects the
arteriolar blood volume in the voxel) (Hua et al., 2011c), we aligned
all nulling and control images to the ﬁrst control image acquired in
the series. Anatomical images were coregisteredwith iVASO images
and normalized to the Montreal Neurological Institute (MNI) space
using SPM. GM, white matter (WM), and cerebrospinal ﬂuid (CSF)
maps were generated from the anatomical images using the SPM
segmentation algorithm. No spatial smoothing was performed in
the analysis. The surround subtraction method (Lu et al., 2006) was
used to calculate the difference signal from the nulling and control
iVASO images. Partial volume effects of WM and CSF on the iVASO
difference signal in GM were corrected (Johnson et al., 2005) (re-
sults without partial volume correction are also reported). An SNR
threshold of one standard deviation below the mean SNR was used
to exclude voxels with insufﬁcient SNR from further analysis (Hua
et al., 2011c). In our data, about 10% of voxels were excluded,
most of which are close to the skull and the sinus regions. This SNR
threshold was applied on each subject’s data. If a voxel falls below
the threshold in one subject, it will be excluded from all subjects in
the group analysis. In our data, most of these voxels overlapped in
multiple subjects. Whole-brain GM CBVa maps were numerically
ﬁtted from the iVASO difference signals at all TIs with the iVASO
equations (Hua et al., 2011c) using in-house MATLAB code.
2.5. PiBepositron emission tomography
PiB-PET was used to estimate individual brain Ab plaque load as
described in earlier publications (Quevenco et al., 2017; van Bergen
et al., 2016). In brief, an individual dose of approximately 350 MBq
of carbon-labeled PiB was injected into the cubital vein. A standard
quantitative ﬁltered back projection algorithm including necessary
corrections was applied. Cortical late frame (minutes 50e70) values
were divided by the cerebellar GM average, resulting in PiB-PET
relative standard uptake values (SUVr; matrix ¼ 128  128  47,
voxel size ¼ 2.3  2.3  3.3 mm3). Measures of individual regional
brain Ab load were derived from the ratio of regional PiB-SUV,
referenced to cerebellar SUV, after coregistration of PET images to
the 7T MP2RAGE volumes using SPM 12 software.
2.6. Statistics
Group differences in GM CBVa maps were examined using
analysis of variance with age, sex, education, regional GM volume
from anatomical scans and motion parameters estimated from the
motion correction (realignment) routine in SPM accounted for as
covariates in the analysis. Signiﬁcant clusters of increased or
decreased GM CBVa were identiﬁed using in-house MATLAB code
implemented using the threshold-free cluster enhancement
method (Smith and Nichols, 2009). Brieﬂy, permutation testing was
conducted by testing the threshold-free cluster enhancement
output against the null distribution across permutations and
obtaining the 95th percentile in the null distribution as the cor-
rected p < 0.05 level. The IBASPM 116 atlas (Lancaster et al., 1997,
2000; Maldjian et al., 2003, 2004; Tzourio-Mazoyer et al., 2002)
(PickAtlas software, Wake Forest University, North Carolina, USA)
was used to identify anatomical regions within the signiﬁcant
clusters. Effect size was estimated with Cohen’s d. Correlations
between CBVa values and Ab (PiB ratio) in each region, as well as
APOE4 carrier status were evaluated using data combined from all
participants (including both MCI and controls). Partial correlations
were calculated with age, sex, and education as covariates. All
statistical tests were corrected for multiple comparisons by con-
trolling the false discovery rate (adjusted p < 0.05) (Benjamini and
Hochberg,1995). Multiple regressionwas carried out usingMATLAB
to test the potential synergistic effects from GM CBVa and Ab (re-
ﬂected in the b3 term in the following equation) on longitudinal
cognitive decline using the following model:
Cognitive decline ð% per yearÞ ¼ b0þ b1  CBVaþ b2 Ab
þ b3 CBVa  Abþ b4
 sex þ b5  age þ b6
 educationþ b7  age
 Ab
In addition, multilevel regression analysis using data from the
control and MRI subjects as 2 separate groups was also performed.
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3. Results
As shown in Table 1, age, sex, and education levels werematched
between patients with MCI and controls (p > 0.1). No signiﬁcant
differences were found in motion parameters derived from the SPM
realignment routine between the 2 groups. Performance in the
Verbal Learning And Memory Test and Mini-Mental State Exami-
nation tests differed between controls and MCI both at study in-
clusion (TP1) and follow-up (TP2) (Supplement 3, Table 9, Fig. S2).
Although there was considerable variability in % changes of per-
formance from TP1 to TP2 on an individual level (Table 1), no sig-
niﬁcant changes between TP1 and TP2 resulted for any of the
investigated tests on a group level (Table 9, Fig. S2). None of the
participants progressed to AD dementia from TP1 to TP2. Partici-
pants of the MCI group had a higher prevalence of hyper-
cholesterinemia and a trend for higher prevalence of arterial
hypertension (Table 1). An individual subject level iVASO CBVamap
from one control subject is shown in Fig. 1 to demonstrate typical
data quality.
Tables 2 and 3 summarizes the main ﬁndings in the group
comparisons. The average GM CBVa values in controls were all in
normal range (Hua et al., 2011c, 2018), providing validation for our
measurements. Widespread elevation of GM CBVa was detected in
many brain regions in patients with MCI compared with controls
with relative changes of 17.0%e122.0% and effect sizes of 0.75e1.56.
Most of these changes were detected in both hemispheres in cor-
responding regions, although the cluster sizes varied between the
left and right hemispheres in some regions. Signiﬁcant reduction of
GM CBVa was also observed in a few brain regions, but the spatial
extent was much smaller than increased CBVa. Some brain regions
showed both decreased and increased GM CBVa values in different
subregions. No signiﬁcant difference was found in mean GM CBVa
over the whole brain (including all GM voxels, not just signiﬁcant
clusters) between patients and controls. The partial volume
correction procedure did not seem to have a major effect on the
measured CBVa values (Table 3). Fig. 2A displays the regions with
signiﬁcant increased or decreased GM CBVa in patients with MCI on
MNI normalized anatomical images, with an intensity reﬂecting the
relative changes in each signiﬁcant voxel. Fig. 2B shows the areas
with signiﬁcantly increased PiB-PET retention in patients with MCI
on MNI normalized anatomical images.
From the correlation analysis, many regionswith increased CBVa
values colocalized with regions with increased Ab deposition, with
signiﬁcant positive correlations between the 2 in several brain re-
gions (Table 4, Fig. 2C). Scatter plots from 2 of these regions are
shown in Fig. 3. In most of these regions, synergistic effects from
GM CBVa and Ab on longitudinal cognitive decline were found
using multiple regression (Tables 5 and 6 and Fig. S1). In regions
with only signiﬁcant CBVa or Ab changes, no such synergistic effects
were found. In addition, GM CBVa in 2 subregions in the orbito-
frontal cortex also showed signiﬁcant positive correlation with
APOE4 carrier status (Supplement 1, Table 7, Fig. 3). Here, by
applying multiple regression analysis, synergistic effects from GM
CBVa and APOE4 on cognitive decline in multiple brain regions
were found (Supplement 2, Table 8). Sex, age, and education were
included as covariates in the correlation analysis.
4. Discussion
By applying ultrahigh ﬁeld strength MRI at 7T to a study pop-
ulation of nondemented older adults, signiﬁcantly elevated CBVa in
patients with MCI could be observed. Interestingly, for the entire
study population, an association between high local deposition of
Ab, as measured by 11C-PiB-PET, and elevated CBVa, asmeasured by
iVASO at 7T 2 years later, was observable in many brain regions.
Moreover, Ab burden and CBVa at follow-up in several brain regions
synergistically predicted cognitive performance over 2 years, when
applying a linear regression model. Consistently, CBVa in the orbi-
tofrontal cortex also showed a synergistic interaction with APOE4
carrier status regarding its relationship to cognitive change.
For this study, ultrahigh ﬁeld strength MRI at 7T was used to
acquire MP2RAGE structural images and 3D iVASO data for
measuring whole-brain absolute CBVa maps (Donahue et al., 2010;
Hua et al., 2011c, 2014, 2017; Marques et al., 2010; Van de Moortele
et al., 2009;Wu et al., 2016). The combination of these technologies
allows for high-resolution assessment of the homeostasis of pial
arteries and arterioles in ﬁne brain regions (Hua et al., 2018).
Regional distribution of Abwas investigated by 11C-PiB-PET as used
by many earlier studies to investigate disease burden in preclinical
and clinical stages of sporadic AD (Jansen et al., 2015; Klunk et al.,
2004). The signiﬁcantly higher burden of Ab and its distribution
pattern in the MCI group are consistent with earlier reports on
pathological change in the predementia stage of AD (Jansen et al.,
2015; Klunk et al., 2004; Roberts et al., 2017). Information on
regional Ab was complemented by assessment of the APOE4 ge-
notype, which is the strongest known genetic risk factor for spo-
radic AD (Corder et al., 1993; Kantarci et al., 2012; Strittmatter et al.,
1993). As a general indicator of cognitive performance in the study
population, 4 German language versions of neuropsychological
tests were performed to generate a composite score that integrates
episodic memory, language, working memory, and executive
function, as a representation of major domains affected early in AD
(Albert et al., 2011). Our ﬁnding of lower test scores at follow-up in
some study participants within the control groupmay reﬂect subtle
cognitive changes associated with normal aging (Harada et al.,
2013) or alternatively could be caused by nonspeciﬁc variation
within the high-performance range of the used tests.
To our knowledge, this is the ﬁrst report of microvascular ab-
normalities speciﬁcally in pial arteries and arterioles in GM
(measured with CBVa) in an elderly, nondemented population at
risk for AD. Although reductions in CBV and CBF have been reported
earlier for AD dementia (Harris et al., 1996; Hauser et al., 2013;
Lacalle-Aurioles et al., 2014; Nielsen et al., 2017b; Uh et al., 2010),
investigations of neurovascular dysfunction in early, prodromal
disease stages so far mainly have been focused on total CBV and CBF,
which include arteriolar, capillary, and venular vessels (Gietl et al.,
2015; Kisler et al., 2017; Leeuwis et al., 2017). Here, our ﬁndings of
increased CBVa in older patients with MCI may be consistent with
earlier reports suggesting an interaction of microvascular abnor-
malities and neurodegenerative pathology in AD (Iadecola and
Fig. 1. Individual subject level CBVa map obtained using iVASO MRI in one control
subject. Abbreviations: CBVa, arteriolar cerebral blood volume; iVASO, inﬂow-based
vascular space occupancy; MRI, magnetic resonance imaging.
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Nedergaard, 2007; Kisler et al., 2017; Schreiner et al., 2018). The
close relationship between CBVa changes and local Ab deposits in
our data is in agreement with earlier considerations of consecutive
vascular damage, impaired cerebrovascular autoregulation, and
effects attributable to Ab toxicity (Brickman et al., 2015; Zlokovic,
2011). In addition, our ﬁnding of a signiﬁcant interactive effect of
CBVa and Ab in several brain regions on cognitive performance over
2 years, as measured by linear regression analysis, corroborates the
relevance of vascular change for functional decline due to AD pa-
thology (Helzner et al., 2009). Such interactive effect was not found
in regions without overlapping CBVa or Ab changes. Concordantly,
we also ﬁnd a synergistic effect of CBVa and APOE4 on cognitive
performance over time, which may indicate relevance of increased
CBVa regarding the individual risk to develop AD dementia. Our
observation of a relationship between increased CBVa with Ab and
also APOE4 may reﬂect impaired cerebrovascular regulation,
possibly caused by a direct impact of toxic Ab aggregates on cere-
bral vessel walls (Kisler et al., 2017). Considering reports on a sig-
niﬁcant role of interstitial bulk ﬂow for clearance of Ab and other
neurodegenerative proteins from the central nervous system that
involves bidirectional CSF movement through paravascular spaces
of pial arteries (Iliff et al., 2012), further preclinical studies are
needed to investigate whether vasodilatation and thus increased
CBVa might be caused by direct toxic impact of Ab. Considering
pathological changes of CBVa as a potential consequence of initial
Ab toxicity, iVASO might represent a marker of secondary cere-
brovascular “downstream” pathology, as demanded recently for
prospective clinical trials that allow for comorbid pathology in AD
(Rabinovici et al., 2017). Alternatively, impaired arterial pulsation
might reduce paravascular drainage of Ab and as such could be
consistent with the notion of a relationship between deteriorated
microvascular hemodynamics and buildup of AD pathology
(Iadecola, 2003; Nielsen et al., 2017b). Moreover, our observation of
an association between APOE4, increased CBVa, and cognitive
decline might also conﬁrm earlier reports of APOE4 as a modulator
of harmful Ab effects on cognitive function (Kantarci et al., 2012).
Consistently, brain regions with signiﬁcant correlations between
CBVa and Ab in our study included the neocortex and hippocampal
formation, which are considered particularly susceptible for AD
pathology (Murray et al., 2015).
Table 2
GM CBVa in patients with MCI compared with controls in various brain regions
Regiona Hemisphere Cluster sizeb Cluster peakc (mm,
MNI)
CBVa (mL blood/100 mL
tissue)
Relative change (%)d Effect sizee Adjusted p value
MCI Control
x y z Mean std Mean std
Frontal_Sup_Orb R 89 22 16 14 2.75 1.88 1.32 1.11 108.2 1.00 0.015
Frontal_Sup_Orb L 86 18 22 14 1.85 1.28 1.01 0.93 82.1 0.79 0.042
Frontal_Inf_Oper R 239 54 12 14 1.54 0.43 1.08 0.25 41.8 1.40 0.049
Frontal_Inf_Oper L 372 46 14 2 1.34 0.28 1.09 0.14 23.7 1.26 0.004
Frontal_Inf_Tri R 498 52 22 24 2.27 1.62 1.25 0.99 81.3 0.82 0.042
Frontal_Inf_Tri L 752 56 22 2 1.90 0.79 1.27 0.52 49.5 1.01 0.013
Frontal_Inf_Orb R 557 32 30 8 2.65 1.63 1.19 0.82 122.0 1.23 0.005
Frontal_Inf_Orb L 200 48 20 8 2.15 1.44 1.07 0.99 100.8 0.93 0.019
Frontal_Sup_Medial R 504 4 42 36 2.44 1.24 1.31 0.91 86.1 1.10 0.050
Frontal_Sup_Medial L 390 12 48 14 2.13 1.14 1.20 0.75 78.3 1.04 0.048
Frontal_Mid_Orb R 346 2 22 12 1.85 1.04 1.12 0.60 65.3 0.93 0.018
Frontal_Mid_Orb L 178 6 38 8 1.89 0.91 1.27 0.67 49.1 0.82 0.028
Rolandic_Oper R 265 40 28 18 1.70 0.65 1.21 0.36 40.2 1.02 0.050
Rolandic_Oper L 417 54 2 4 1.63 0.52 1.23 0.20 33.1 1.15 0.010
Supp_Motor_Area R 136 2 4 54 1.20 0.26 0.99 0.12 21.3 1.17 0.008
Supp_Motor_Area L 78 0 6 56 1.22 0.31 1.00 0.18 22.2 0.94 0.022
Olfactory R 161 4 14 14 2.31 1.19 1.13 0.81 103.9 1.24 0.003
Olfactory L 146 4 20 14 2.06 1.11 1.08 0.80 90.1 1.07 0.008
Rectus R 81 10 18 14 2.46 1.17 1.16 1.01 111.4 1.24 0.002
Rectus L 59 8 22 12 2.16 1.17 1.11 0.86 94.7 1.09 0.007
Insula R 979 36 18 12 2.39 1.13 1.23 0.69 93.5 1.33 0.002
Insula L 761 36 24 8 2.25 1.30 1.33 0.78 69.6 0.93 0.022
Cingulum_Ant R 311 12 36 8 2.16 1.12 1.29 0.94 66.8 0.88 0.029
Cingulum_Ant L 504 8 34 18 2.22 1.13 1.32 0.81 67.9 0.97 0.022
Cingulum_Mid R 499 6 8 44 1.21 0.16 1.04 0.07 17.0 1.56 0.001
Cingulum_Mid L 338 4 2 40 1.30 0.23 1.08 0.11 20.3 1.35 0.003
Hippocampus R 56 28 36 8 1.78 0.93 1.05 0.57 69.2 1.01 0.014
Hippocampus L 84 22 26 12 1.76 0.84 1.08 0.65 63.9 0.96 0.013
Lingual R 35 22 50 2 2.35 0.88 1.79 0.69 31.4 0.75 0.047
Lingual L 47 22 56 4 1.37 0.47 1.08 0.15 26.9 0.94 0.035
Caudate R 209 14 10 12 2.34 1.65 1.16 1.17 101.4 0.88 0.026
Caudate L 178 10 18 10 2.26 1.61 1.17 1.31 93.3 0.78 0.039
Putamen R 422 24 22 8 1.93 1.25 1.06 0.79 82.7 0.90 0.025
Putamen L 441 28 2 4 2.40 1.38 1.51 1.01 58.7 0.78 0.044
Temporal_Sup R 518 54 0 14 1.88 0.86 1.25 0.50 50.2 0.97 0.019
Temporal_Sup L 955 56 4 2 1.83 0.91 1.17 0.36 56.3 1.05 0.017
Temporal_Pole_Sup R 272 50 14 12 2.46 1.33 1.30 0.76 88.5 1.16 0.006
Temporal_Pole_Sup L 205 58 6 4 2.00 1.20 1.01 0.64 98.1 1.12 0.009
Key: CBVa, arteriolar cerebral blood volume; GM, gray matter; MCI, mild cognitive impairment; MNI, Montreal Neurological Institute; std, standard deviation.
a The brain regions were labeled according to the IBASPM 116 atlas (please see Methods for references).
b Number of voxels that shows signiﬁcant group difference in this region.
c Location of the voxel with the maximum (peak) T-score in the cluster in the MNI space.
d Relative change was deﬁned as 100 * (mean CBVa in MCIemean CBVa in controls)/(mean CBVa in controls) %.
e Effect size was estimated with Cohen’s d ¼ (mean CBVa in MCIemean CBVa in controls)/s, where s is the pooled standard deviation of the 2 groups.
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The signiﬁcant CBVa increase observed here may appear con-
tradictorywith thewell-established ﬁnding of reduced regional CBF
in MCI (Alsop et al., 2010; Dvorak et al., 1999; Hirao et al., 2005;
Roher et al., 2011; Ruitenberg et al., 2005; Thomas et al., 2015).
Ab has long been known as a powerful vasoconstrictor (Niwa et al.,
2001). However, we think that our increased CBVa ﬁnding may be
congruent with CBF reduction for the reasons explained subse-
quently. Note that CBV measured by MRI reﬂects the fractional
volume of all blood vessels in a given voxel (i.e., the unit of CBV: mL
blood per 100 mL tissue). Therefore, CBV is proportional to the
cross-sectional vessel diameter, length of blood vessels, and overall
number of blood vessels in the voxel. A decrease in cross-sectional
vessel diameter often leads to a decrease in CBF (vasoconstriction).
However, if the vessel density in the voxel increases (thus increased
number of vessels) possibly due to angiogenesis or others, the
overall CBV measured in the voxel can be increased. Indeed, recent
studies in tau-overexpressing mice showed increased blood vessel
volume (increased CBV) but reduced blood vessel diameter
(reduced CBF) compared with controls (Bennett et al., 2018). In the
cortex of these mice, overall blood vessel density was increased
compared with controls even when the cortical atrophy is
accounted for and blood ﬂowwas altered and at times obstructed in
some vessels. A qPCR assay revealed that several genes related to
hypoxia and angiogenesis were increased more than 2 fold in these
mice. Although these results were obtained in tau-overexpressing
mice (rather than amyloid-based models), they indicate a possible
explanation for the concomitant CBVa increase and CBF reduction.
Besides, the uncoupling of CBF and CBV is often seen in circum-
stances in which there is increased metabolic demand or hypoxia
and angiogenesis (Mishra, 2016; Puro et al., 2016); for instance, in
ischemia, the pial arteries and arterioles are typically dilated to
compensate for a lack of blood ﬂow, so a situation of reduced CBF,
with increased CBVa. Another possibility is elevated microvascular
tortuosity (Thore et al., 2007), thus increased length of blood ves-
sels. These hypotheses should be validated in future studies
possibly combining MRI with other imaging techniques such as
optical imaging. Second, as CBVa represents arteriolar fractions of
total CBV (sum of arteriolar, capillary, and venular CBV), a distinct
increase of CBVa might indicate a shift of volumes within the ce-
rebrovascular system. Different types of blood vessels have distinct
Table 3
GM CBVa in patients with MCI compared with controls in various brain regions (without partial volume correction)
Regiona Hemisphere Cluster sizeb Cluster peakc (mm,
MNI)
CBVa (mL blood/100 mL
tissue)
Relative change (%)d Effect sizee Adjusted p value
MCI Control
x y z Mean std Mean std
Frontal_Sup_Orb R 89 22 16 14 2.48 1.70 1.22 1.02 104.1 0.98 0.020
Frontal_Sup_Orb L 86 18 22 14 1.67 1.16 0.93 0.86 78.5 0.76 0.046
Frontal_Inf_Oper R 239 54 12 14 1.36 0.38 0.97 0.22 40.3 1.36 0.050
Frontal_Inf_Oper L 372 46 14 2 1.21 0.25 0.98 0.13 22.8 1.22 0.005
Frontal_Inf_Tri R 498 52 22 24 2.04 1.46 1.13 0.89 80.6 0.81 0.043
Frontal_Inf_Tri L 752 56 22 2 1.68 0.70 1.17 0.48 43.9 0.92 0.016
Frontal_Inf_Orb R 557 32 30 8 2.34 1.44 1.08 0.75 116.0 1.19 0.006
Frontal_Inf_Orb L 200 48 20 8 1.92 1.29 0.99 0.91 94.9 0.89 0.023
Frontal_Sup_Medial R 504 4 42 36 2.22 1.13 1.18 0.82 87.9 1.12 0.051
Frontal_Sup_Medial L 390 12 48 14 1.90 1.02 1.08 0.68 75.7 1.01 0.051
Frontal_Mid_Orb R 346 2 22 12 1.66 0.93 1.01 0.54 65.0 0.93 0.020
Frontal_Mid_Orb L 178 6 38 8 1.68 0.81 1.14 0.61 47.1 0.80 0.032
Rolandic_Oper R 265 40 28 18 1.54 0.58 1.12 0.33 37.4 0.96 0.054
Rolandic_Oper L 417 54 2 4 1.45 0.46 1.12 0.19 29.5 1.04 0.015
Supp_Motor_Area R 136 2 4 54 1.08 0.23 0.91 0.11 19.1 1.07 0.012
Supp_Motor_Area L 78 0 6 56 1.10 0.28 0.90 0.16 22.5 0.95 0.023
Olfactory R 161 4 14 14 2.10 1.08 1.04 0.75 100.9 1.21 0.006
Olfactory L 146 4 20 14 1.87 1.01 0.99 0.73 89.1 1.06 0.009
Rectus R 81 10 18 14 2.20 1.05 1.05 0.92 109.3 1.22 0.002
Rectus L 59 8 22 12 1.91 1.03 1.01 0.78 89.1 1.04 0.010
Insula R 979 36 18 12 2.11 1.00 1.12 0.63 88.7 1.28 0.004
Insula L 761 36 24 8 2.00 1.16 1.19 0.70 67.8 0.92 0.025
Cingulum_Ant R 311 12 36 8 1.95 1.02 1.17 0.85 67.4 0.88 0.033
Cingulum_Ant L 504 8 34 18 1.97 1.00 1.19 0.72 65.8 0.95 0.025
Cingulum_Mid R 499 6 8 44 1.10 0.15 0.93 0.06 17.5 1.60 0.004
Cingulum_Mid L 338 4 2 40 1.16 0.20 0.98 0.10 18.3 1.23 0.007
Hippocampus R 56 28 36 8 1.61 0.85 0.95 0.52 69.2 1.01 0.018
Hippocampus L 84 22 26 12 1.57 0.75 0.96 0.58 62.8 0.95 0.016
Lingual R 35 22 50 2 2.09 0.78 1.65 0.63 26.3 0.64 0.048
Lingual L 47 22 56 4 1.22 0.42 1.00 0.13 22.0 0.79 0.036
Caudate R 209 14 10 12 2.10 1.48 1.06 1.07 98.9 0.86 0.030
Caudate L 178 10 18 10 2.02 1.44 1.06 1.19 90.0 0.76 0.039
Putamen R 422 24 22 8 1.72 1.11 0.96 0.71 79.8 0.88 0.027
Putamen L 441 28 2 4 2.17 1.25 1.39 0.93 55.8 0.75 0.045
Temporal_Sup R 518 54 0 14 1.69 0.77 1.14 0.46 48.8 0.94 0.024
Temporal_Sup L 955 56 4 2 1.64 0.82 1.05 0.33 56.0 1.05 0.020
Temporal_Pole_Sup R 272 50 14 12 2.23 1.21 1.20 0.70 86.3 1.14 0.009
Temporal_Pole_Sup L 205 58 6 4 1.78 1.07 0.92 0.58 94.1 1.09 0.011
Key: CBVa, arteriolar cerebral blood volume; GM, gray matter; MCI, mild cognitive impairment; MNI, Montreal Neurological Institute; std, standard deviation.
a The brain regions were labeled according to the IBASPM 116 atlas (please see Methods for references).
b Number of voxels that show signiﬁcant group difference in this region.
c Location of the voxel with the maximum (peak) T-score in the cluster in the MNI space.
d Relative change was deﬁned as 100 * (mean CBVa in MCIemean CBVa in controls)/(mean CBVa in controls) %.
e Effect size was estimated with Cohen’s d ¼ (mean CBVa in MCIemean CBVa in controls)/s, where s is the pooled standard deviation of the 2 groups.
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functions and physiology and can be affected differentially by the
AD pathology. The arterioles are the most actively regulated blood
vessels and thus may be more sensitive to metabolic disturbances
in the brain (Iadecola and Nedergaard, 2007; Ito et al., 2001, 2005;
Kim et al., 2007; Takano et al., 2006). For instance, signiﬁcant
reduction in CBVa has been observed in patients with schizophrenia
(Hua et al., 2015, 2017), whereas no substantial changes in capil-
laries were indicated in histopathological studies in schizophrenia
(Kreczmanski et al., 2005, 2009; Uranova et al., 2010). It should be
noted that small diameter (<150 microns) pial arteries and arteri-
oles (CBVa) only represents 10%e20% of total CBV (Hua et al., 2018;
Piechnik et al., 2008; Sharan et al., 1989; van Zijl et al., 1998)
(depending on vessel diameter), thus an 100% increase in CBVa
would only translate to 10%e20% in total CBV change, which is
within the typical physiological range. The fact that CBVa values in
controls were all within the normal range (Hua et al., 2018) and that
CBVa in the cerebellum (which is not expected to be affected at this
stage) did not showgroup differences also provides some validation
for our results. Further studies are needed to investigate whether
increase of CBVa in AD risk populations might possibly result in
reduced total CBV in clinically manifest AD, as reported earlier
(Eskildsen et al., 2017; Hauser et al., 2013; Lacalle-Aurioles et al.,
2014; Nielsen et al., 2017b; Yoshiura et al., 2009). It is also worth
noting that the synergetic effects between CBVa and other pa-
rameters were restricted to several small brain regions, which
might be in agreement with the recent observation of regional AD-
like biomarker patterns in at-risk populations (Wirth et al., 2017).
Moreover, in our study, higher prevalence of hyperlipidemia were
Fig. 2. (A) Map of relative CBVa changes between patients with MCI and controls overlaid on MNI normalized anatomical images. The relative change is deﬁned as (100 
[MCIcontrol]/control)%. Only voxels that show signiﬁcant CBVa difference between the 2 groups (adjusted p < 0.05) are highlighted. (B) Brain regions with abnormal PiB-PET
retention overlaid on MNI normalized anatomical images. Only voxels that show signiﬁcant PiB-PET difference between patients with MCI and controls (adjusted p < 0.05) are
highlighted. (C) Colocalization of GM CBVa abnormality and b-amyloid deposit. Voxels that show signiﬁcant correlation between GM CBVa values and PiB ratios are highlighted
overlaid on MNI normalized anatomical images. Abbreviations: CBVa, arteriolar cerebral blood volume; GM, gray matter; MCI, mild cognitive impairment; MNI, Montreal
Neurological Institute; MRI, magnetic resonance imaging; PiB-PET, 11C Pittsburgh compound-B positron emission tomography.
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observable for the MCI group, which may be consistent with earlier
reports on an association between serum hypercholesterolemia
and increased risk for the development of AD amyloid pathology
(Pappolla et al., 2003).
It is important to discuss methodological factors for iVASO MRI,
which might interact with MCI pathology to bias the study results.
First, the presence of amyloid may introduce additional suscepti-
bility effects at high ﬁeld that can affect MR signals. Fortunately, in
iVASO, CBVa is calculated from the difference signal between the
arteriolar blood nulled image and the subsequent control image.
Therefore, all static signals that are not ﬂowing such as GM andWM
should cancel out on subtraction (Hua et al., 2011b). Second, dif-
ferences in cortical thickness among groups or over time may lead
to different partial volume effects in the CBVa results. As this is an
important confounding factor especially in this population inwhich
substantial brain atrophy is expected, we corrected such partial
volume effects in our analysis using a previously published method
(Johnson et al., 2005) (see Methods Section). In addition, GM vol-
ume derived from anatomical images was included as a covariate in
all statistical analyses to account for any residual partial volume
effects. As shown in the Results Section, all major ﬁndings were
consistent with and without the partial volume correction step. It is
important to realize that iVASO MRI does not measure CBV in the
capillaries (Hua et al., 2018) but only in the arterial compartment.
This predominant arterial origin of the iVASO signal was validated
Table 4
Correlation between GM CBVa and b-amyloid in multiple brain regions in all
participants
Regiona Estimate coefﬁcient Standard error p-Value
Frontal_Sup_Orb 2.32 0.38 <0.001
Frontal_Inf_Oper 0.31 0.14 0.006
Frontal_Inf_Orb 4.69 2.36 0.01
Frontal_Sup_Medial 3.33 1.32 0.006
Frontal_Mid_Orb 1.16 0.23 <0.001
Rolandic_Oper 0.67 0.26 0.001
Supp_Motor_Area 0.17 0.10 0.05
Cingulum_Ant 2.64 1.36 0.01
Cingulum_Mid 0.23 0.06 <0.001
Hippocampus 4.49 2.46 0.03
Lingual 1.70 0.86 0.01
Key: CBVa, CBVa, arteriolar cerebral blood volume; GM, gray matter.
a The brain regions were labeled according to the IBASPM 116 atlas (please see
Methods for references).
Fig. 3. Scatter plots show correlations between CBVa and b-amyloid, and boxplots show associations between CBVa, the number of APOE-e4 alleles, and between b-amyloid and the
number of APOE-e4 alleles in the superior orbitofrontal cortex (Frontal_Sup_Orb, A-C) and the middle orbitofrontal cortex (Frontal_Mid_Orb, D-F), respectively. These 2 regions
showed signiﬁcant correlations between CBVa and both b-amyloid (Table 4) and number of APOE-e4 alleles (Supplement 1, Table 7). Several additional regions showed signiﬁcant
correlation between CBVa and b-amyloid (Table 4) but not between CBVa and number of APOE-e4 alleles. The trend lines and adjusted R2 and P were obtained from linear regression
using data combined from all participants. Abbreviations: APOE-e4, apolipoprotein E e4; CBVa, arteriolar cerebral blood volume; MCI, mild cognitive impairment; PiB, 11C Pitts-
burgh compound-B.
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previously by measuring the transverse (T2) relaxation time of the
iVASO difference signal, which is highly sensitive to the blood
oxygenation level (Hua et al., 2011b). Given the importance of
capillaries for tissue perfusion in healthy brain and in AD and MCI
(Eskildsen et al., 2017; Nielsen et al., 2017a), future studies should
also investigate potential abnormalities in capillaries in MCI using
specialized methods.
One fundamental limitation of this pilot study is the time dif-
ference between the PET imaging and theMRI scans. To assess long-
term effects of Ab, in the present study, 7T MRI was administered
approximately 2 years after the initial 11C-PiB-PET. Considering the
gradual accumulation of Ab in AD, which takes almost 2 decades
before the threshold-level of pathological Ab characterizing the
clinical syndrome is reached (Dubois et al., 2016; Roberts et al.,
2017), the chosen temporal delay of 2 years should allow for
detecting long-term effects of Ab on CBVa, while still remaining
within the AD predementia phase. However, as currently not much
is known on possible determinants of Ab dynamics in clinical
populations, our ﬁndings of a relationship between local Ab and
CBVa might be affected by possibly existing differences in cerebral
Ab accumulation between study participants. In this regard, our
preliminary results should be interpreted with caution, and both
PET and MRI will be administrated at the initial and the follow-up
visits in subsequent studies to validate the current ﬁndings. In
addition, as our assessment of individual cognitive decline per year
does not account for practice effects or regression to the mean,
effects associated with cognition need to be interpreted with
caution and replicated by prospective longitudinal studies.
Another important limitation of the study is that all variables,
including APOE4 status, were treated as linear in the multiple
regression analysis. While such linear mixed models are commonly
adopted in similar studies (Mormino et al., 2014), they may not
reﬂect accurate relationship between cognitive decline and these
variables. More detailed modeling is merited in subsequent studies
to explore and describe more precise relationships between these
measures.
Finally, it is possible that PET SUVr may show correlation with
CBF simply because the PET tracer reaches its target via the blood
ﬂow. However, as we assessed the steady state effect with cortical
late-frames for estimating SUVr, that is, 50e70 minutes after 11C-
PiB injection, inﬂuence from the dynamic relationship between 11C
PiB SUVr and CBF at earlier TPs should be negligible. Indeed, it has
been shown that 11C-PiB retention did not correlate with regional
CBF (Chen et al., 2015). Moreover, according to the central volume
theorem, CBF ¼ CBVa/arterial transit time (ATT), such dynamic
interaction between CBF and PET SUVr should primarily be driven
by changes in ATT. In iVASO, heterogeneity of ATT is accounted for
with data acquired at multiple TIs and the ﬁtting algorithm in the
iVASO theory (Hua et al., 2011c). Therefore, the correlation between
CBVa and PET SUVr observed in our data should be minimally
affected by the potential interaction between CBF and PET SUVr.
Although in our data only regional interactions between 11C-PiB
SUVr and CBVa were observable, the possibility of a general con-
founding effect on quantiﬁcation of the iVASO signal should
nevertheless be considered. In addition, potential interindividual
differences in the susceptibility to Ab burden might be a
Table 5
Multiple regression shows synergistic effects from GM CBVa and b-amyloid on cognitive decline in multiple brain regions
Regiona Standardized coefﬁcientb,c p-Value R2
CBVa (b1) Ab (b2) CBVa  Ab (b3) CBVa (b1) Ab (b2) CBVa  Ab (b3)
Frontal_Sup_Orb
Model 1d (full) 1.47 0.62 1.77 0.05 0.05 0.05 0.31
Model 2e (restricted) 0.27 0.05 0.15
F-test (p)f 0.05
Frontal_Inf_Orb
Model 1d (full) 1.46 1.02 1.76 0.05 0.03 0.05 0.39
Model 2e (restricted) 0.51 0.05 0.16
F-test (p)f 0.01
Frontal_Sup_Medial
Model 1d (full) 1.52 0.97 2.14 0.02 0.02 0.01 0.36
Model 2e (restricted) 0.45 0.04 0.15
F-test (p)f 0.01
Frontal_Mid_Orb
Model 1d (full) 0.70 1.02 1.75 0.05 0.02 0.05 0.45
Model 2e (restricted) 0.43 0.05 0.17
F-test (p)f 0.002
Supp_Motor_Area
Model 1d (full) 1.39 1.84 2.47 0.03 0.03 0.03 0.37
Model 2e (restricted) 0.38 0.04 0.15
F-test (p)f 0.01
Hippocampus
Model 1d (full) 3.52 0.71 4.78 0.01 0.05 0.01 0.35
Model 2e (restricted) 0.29 0.05 0.15
F-test (p)f 0.05
Lingual
Model 1d (full) 2.76 1.19 2.96 0.05 0.03 0.05 0.33
Model 2e (restricted) 0.37 0.04 0.15
F-test (p)f 0.03
Key: Ab, b-amyloid; CBVa, CBVa, arteriolar cerebral blood volume; GM, gray matter.
a The brain regions were labeled according to the IBASPM 116 atlas (please see Methods for references).
b The estimated coefﬁcients correspond to b1, b2, and b3 in Equation for CBVa, Ab, and CBVa Ab, respectively. The synergistic effect from CBVa and Ab is reﬂected in the b3
term.
c The standardized coefﬁcient can be used as an estimate of relative contribution to longitudinal cognitive decline from each term.
d Model 1: cognitive decline (% per year) ¼ b0 þ b1  CBVa þ b2  Ab þ b3  CBVa  Ab þ b4  sex þ b5  age þ b6  education.
e Model 2: cognitive decline (% per year) ¼ b0 þ b2  Ab þ b4  sex þ b5  age þ b6  education.
f p-Value from R2 change F-test to assess whether the R2 from the 2 models are signiﬁcantly different.
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confounding factor (van Bergen et al., 2018a). Furthermore, because
of the highly specialized experimental setup including both 7T MRI
and 11C-PiB, which needed to be performed in the vicinity of the
cyclotron used for manufacturing the tracer, a multi-center
approach was not feasible, resulting in a relatively small sample
size. However, while the application of ultrahigh ﬁeld strength MRI
for maximizing SNR may have increased power to detect early Ab-
related CBVa changes, future larger studies are needed to reproduce
our ﬁndings in a more clinical setting.
5. Conclusion
Taken together, we here provide evidence on increases in CBVa
that are observable in older adults with MCI and closely relate to
local Ab, APOE4, and cognitive decline within 2 years. Although our
data support earlier considerations on a close relationship between
AD pathology and neurovascular dysfunction, additional research is
needed to investigate whether elevated CBVa in the predementia
stage of AD may represent a marker of secondary vascular pathol-
ogy associated with Ab accumulation and thus resulting damage to
the neurovascular unit. Alternatively, increased CBVa in the pre-
dementia stage may represent a compensatory mechanism aimed
at maintaining stable cerebral perfusion and oxygen supply despite
spreading AD pathology.
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